

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer














